Terns Pharmaceuticals to Present Positive Clinical Data in NASH at AASLD The Liver Meeting® 2022

Rhea-AI Summary

Terns Pharmaceuticals, Inc. (Nasdaq: TERN) announced plans to present two abstracts at the AASLD The Liver Meeting® from November 4-8, 2022. The presentations will focus on TERN-501, a THR-β agonist, and TERN-101, an FXR agonist, both under investigation for treating non-alcoholic steatohepatitis (NASH). The first abstract highlights TERN-501’s effects on sex hormone binding globulin and lipid levels, while the second discusses an ongoing Phase 2a study of TERN-501 and TERN-101 in NASH patients, with top-line results expected in late 2023.

Positive

• Presentation of findings at AASLD could enhance visibility and credibility in the biopharmaceutical community.
• Ongoing Phase 2a trial of TERN-501 alone and in combination with TERN-101, with top-line data expected in late 2023.

Negative

• Dependence on upcoming trial results; any adverse findings could negatively impact stock performance.

FOSTER CITY, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic steatohepatitis (NASH), today announced that the company will present two abstracts regarding its investigational therapies TERN-501, a THR-β agonist, and TERN-101, an FXR agonist, in clinical development for the treatment of NASH at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting^®, which will be held November 4-8, 2022. The poster abstracts were published in the October 2022 supplement of Hepatology, the peer-reviewed journal of AASLD.

Details of the presentations at The Liver Meeting are as follows:

Poster Presentations

Title: Thyroid Hormone Beta Receptor Agonist TERN-501 Demonstrates Dose- and Exposure-Dependent Increases in Sex Hormone Binding Globulin With Associated Decreases in Atherogenic Lipids in Healthy Subjects
Poster Number: 2353
Session Title: Poster Session II
Presenting Author: Cara Nelson, Ph.D., Terns Pharmaceuticals

Title: Trial in Progress: The First 12-Week, Randomized, Controlled Phase 2a Study of a Thyroid Hormone Receptor-β agonist (TERN-501) Administered as Monotherapy or in Combination With a Farnesoid X Receptor Agonist (TERN-101) in Patients With NASH
Poster Number: 2364
Session Title: Poster Session II
Presenting Author: Stephen Harrison, M.D., Pinnacle Clinical Research, San Antonio, TX

About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and NASH. Terns’ pipeline includes four clinical stage development programs including an allosteric BCR-ABL inhibitor, a THR-β agonist, an FXR agonist, a VAP-1 inhibitor, and a preclinical small-molecule GLP-1 receptor agonist program. For more information, please visit: www.ternspharma.com.

About TERN-501
TERN-501 is a thyroid hormone receptor beta (THR-β) agonist with high metabolic stability, enhanced liver distribution and greater selectivity for THR-β compared to other THR-β agonists in development. Agonism of THR-β increases fatty acid metabolism via mitochondrial oxidation and affects cholesterol synthesis and metabolism. As a result, THR-β stimulation has the ability to reduce hepatic steatosis and improve serum lipid parameters including LDL cholesterol and triglycerides. Terns reported positive top-line single-ascending and multiple-ascending dose (SAD/MAD) data from Phase 1 proof of concept clinical trial in November 2021. The DUET Phase 2a clinical trial of TERN-501 alone and in combination with TERN-101 is ongoing, with top-line data expected in the second half of 2023.

About TERN-101
TERN-101 is a liver-distributed, non-bile acid FXR agonist that has demonstrated a differentiated tolerability profile and improved target engagement, likely due to its sustained FXR activation in the liver but only transient FXR activation in the intestine. FXR is a nuclear receptor primarily expressed in the liver, intestine and kidneys. FXR regulates hepatic expression of various genes involved in lipid metabolism, inflammation and fibrosis. Clinical studies of other FXR agonists have demonstrated significant histological NASH improvements but have also resulted in pruritus, adverse lipid changes and discontinuations. Terns reported positive top-line results from the Phase 2a LIFT Study of TERN-101 in June 2021.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements about Terns Pharmaceuticals, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws, including those related to the Company’s expectations of timing and potential results of the Company’s clinical trials and other development activities, such as the Phase 2a DUET trial of TERN-501 alone and in combination with TERN-101; the potential indications to be targeted by the Company with its product candidates; the therapeutic potential of the Company’s product therapy candidates; the potential for the mechanisms of action of the Company’s product candidates to be therapeutic targets for their targeted indications; the potential utility and progress of the Company’s product candidates in their targeted indications, including the clinical utility of the data from and the endpoints used in the Company’s clinical trials; the Company’s clinical development plans and activities; the Company’s expectations regarding the profile of its product candidates, including tolerability, safety, metabolic stability and pharmacokinetic profile and potential differentiation as compared to other products or product candidates; and the Company’s plans for and ability to continue to execute on its current clinical strategy. All statements other than statements of historical facts contained in this press release, including statements regarding the Company’s strategy, future financial condition, future operations, future trial results, projected costs, prospects, plans, objectives of management and expected market growth, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results and the implementation of the Company’s plans to vary materially, including the risks associated with the initiation, cost, timing, progress, results and utility of the Company’s current and future research and development activities and preclinical studies and clinical trials. These risks are not exhaustive. For a detailed discussion of the risk factors that could affect the Company’s actual results, please refer to the risk factors identified in the Company’s SEC reports, including but not limited to its Annual Report on Form 10-K for the year ended December 31, 2021 and its Quarterly Report on Form 10-Q for the periods ended March 31, 2022 and June 30, 2022. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.

Contacts for Terns

Investors
Justin Ng
investors@ternspharma.com

Media
Jenna Urban
Berry & Company Public Relations
media@ternspharma.com

FAQ

What is TERN-501 and its significance in the NASH trial?

TERN-501 is a THR-β agonist being studied for its potential to improve metabolic parameters in patients with NASH.

What are the key details about the TERN-101 study?

TERN-101 is being evaluated in a Phase 2a study alongside TERN-501, with results expected in late 2023.

When and where will Terns Pharmaceuticals present its research?

Terns will present at the AASLD The Liver Meeting®, scheduled for November 4-8, 2022.

How does TERN-501 affect lipid levels?

TERN-501 has shown to result in decreases in atherogenic lipids as indicated in the study.

What could be the market impact of Terns' upcoming data release?

Positive results may lead to increased investor confidence and stock price appreciation.